Skip to main content
. 2019 Aug 20;10(49):5092–5102. doi: 10.18632/oncotarget.27149

Figure 4. JMV/EGF activate ERK 1/2 and MEK.

Figure 4

Immunoblotting of AML12 cell lysates with or without treatment with EGF, the NTS analog JMV 449, or both, as indicated at the top of the figure, using primary antibodies for phospho- and total S6 kinase, phospho- and total p44/42 MAPK (ERK 1/2), phospho- and total MEK 1/2, phospho- and total Src, phospho- and total EGFR, and phospho- and total HER2/ErbB2. Actin is shown as a loading control.